Evaluation of Tigecycline Susceptibility in Multidrug-Resistant Bacteria at the University Hospital of Marrakech (Morocco)

The phenomenon of bacterial resistance to antibiotics is a major public health problem. The prevalence of multidrug-resistant bacteria is rapidly increasing with heavy consequences in terms of morbidity and mortality and health care costs. Tigecycline is a new active glycylcycline on this type of germ and could be a therapeutic alternative for the management of these infections. The aim of this work is to evaluate the in vitro activity of Tigecycline against multidrug-resistant organisms isolated at Mohammed VI hospital in Marrakech. It is a descriptive prospective study of a series of 171 multidrug-resistant bacteria including 102 clinical isolates of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL) and 85 clinical isolates of multidrug-resistant Acinetobacter baumannii. The in vitro activity of Tigecycline was measured by the determination of the minimum inhibitory concentration (MIC) by diffusion method on agar medium using the strips "E-test" according to the recommendations of the CASFM. 71% of Acinetobacter baumannii isolates were sensitive to Tigecycline of with MIC ≤1mg / l, while 17.6% of tested strains had intermediate sensitivity to Tigecycline with a MIC between 1 and 2 mg / l, 11,4% were resistant with a MIC> 2 mg / l. ESBL enterobacterial strains were mostly (77,5%) with a MIC ≤ 1 mg / l. Intermediate sensitivity was found in 15.6% of the isolates with a MIC between 1 and 2 mg / l, however, resistance to Tigecycline was found in 6.8% of enterobacterial isolates with a MIC> 2 mg /l. Tigecycline is an interesting therapeutic option and may have an important role in the treatment of multidrug-resistant infections. Detection of the sensitivity status of Tigecycline is necessary to optimize its use and preserve this molecule in our therapeutic arsenal.